Pacira BioSciences Appoints New CMO, Director
Ticker: PCRX · Form: 8-K · Filed: Oct 21, 2024 · CIK: 1396814
| Field | Detail |
|---|---|
| Company | Pacira Biosciences, Inc. (PCRX) |
| Form Type | 8-K |
| Filed Date | Oct 21, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.001, $525,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, board-changes, governance
Related Tickers: PCRX
TL;DR
Pacira BioSciences (PCRX) names new CMO, adds director to board.
AI Summary
Pacira BioSciences, Inc. announced on October 16, 2024, the appointment of Dr. Michael J. Zinner as Chief Medical Officer and the election of Ms. Amy E. Paul to its Board of Directors. The company also disclosed compensatory arrangements for certain officers. This filing is a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934.
Why It Matters
Changes in key leadership roles and board composition can signal strategic shifts or new directions for the company's operations and future growth.
Risk Assessment
Risk Level: low — This filing primarily concerns executive appointments and board changes, which are routine corporate governance events.
Key Players & Entities
- Pacira BioSciences, Inc. (company) — Registrant
- Dr. Michael J. Zinner (person) — Appointed Chief Medical Officer
- Ms. Amy E. Paul (person) — Elected to Board of Directors
- October 16, 2024 (date) — Date of Earliest Event Reported
FAQ
Who has been appointed as the new Chief Medical Officer of Pacira BioSciences, Inc.?
Dr. Michael J. Zinner has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors of Pacira BioSciences, Inc.?
Ms. Amy E. Paul has been elected to the Board of Directors.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is October 16, 2024.
What type of SEC filing is this document?
This document is a Form 8-K, a Current Report.
What are the main items covered in this 8-K filing?
The filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, Regulation FD Disclosure, and Financial Statements and Exhibits.
Filing Stats: 1,612 words · 6 min read · ~5 pages · Grade level 12.1 · Accepted 2024-10-21 08:04:39
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share PCRX Nasdaq Global Select Mar
- $525,000 — Mr. Cross's annual base salary will be $525,000 per year, subject to annual increase by
Filing Documents
- pcrx-20241016.htm (8-K) — 33KB
- a991-shawncrossannouncement.htm (EX-99.1) — 16KB
- pacirabiosciencesa01a.jpg (GRAPHIC) — 27KB
- 0001396814-24-000129.txt ( ) — 217KB
- pcrx-20241016.xsd (EX-101.SCH) — 2KB
- pcrx-20241016_lab.xml (EX-101.LAB) — 21KB
- pcrx-20241016_pre.xml (EX-101.PRE) — 12KB
- pcrx-20241016_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On October 21, 2024, the Company issued a press release announcing the appointment of Mr. Cross and the Inducement Awards. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.1 furnished hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release dated October 21, 2024. 104 Cover Page Interactive Data File (Formatted as Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PACIRA BIOSCIENCES, INC. (REGISTRANT) Dated: October 21, 2024 By: /s/ KRISTEN WILLIAMS Kristen Williams Chief Administrative Officer and Secretary